Single-agent mTOR inhibitor temsirolimus and everolimus also showed limited efficacy (81, 82), whereas one patient carrying a TSC 1-inactivating mutation treated with everolimus had notable tumor shrinkage and durable response, suggesting the blockade of the PI3K/mTOR axis could improve outcome in some specific patients (83). This evidence concerns the gene PIK3CA and neoplasm.